- Home
- AMBO vs DWTX Comparison
AMBO vs DWTX Comparison
Compare AMBO & DWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBO
- DWTX
- Stock Information
- Founded
- AMBO 2000
- DWTX 2012
- Country
- AMBO United States
- DWTX United States
- Employees
- AMBO N/A
- DWTX N/A
- Industry
- AMBO Other Consumer Services
- DWTX
- Sector
- AMBO Real Estate
- DWTX
- Exchange
- AMBO Nasdaq
- DWTX NYSE
- Market Cap
- AMBO 7.1M
- DWTX 5.9M
- IPO Year
- AMBO 2010
- DWTX N/A
- Fundamental
- Price
- AMBO $2.56
- DWTX $5.66
- Analyst Decision
- AMBO
- DWTX Strong Buy
- Analyst Count
- AMBO 0
- DWTX 1
- Target Price
- AMBO N/A
- DWTX $10.00
- AVG Volume (30 Days)
- AMBO 11.6K
- DWTX 2.4M
- Earning Date
- AMBO 12-30-2024
- DWTX 05-14-2025
- Dividend Yield
- AMBO N/A
- DWTX N/A
- EPS Growth
- AMBO N/A
- DWTX N/A
- EPS
- AMBO 0.11
- DWTX N/A
- Revenue
- AMBO $9,392,000.00
- DWTX N/A
- Revenue This Year
- AMBO N/A
- DWTX N/A
- Revenue Next Year
- AMBO N/A
- DWTX N/A
- P/E Ratio
- AMBO $23.56
- DWTX N/A
- Revenue Growth
- AMBO 2.50
- DWTX N/A
- 52 Week Low
- AMBO $1.00
- DWTX $1.62
- 52 Week High
- AMBO $5.55
- DWTX $29.28
- Technical
- Relative Strength Index (RSI)
- AMBO 47.49
- DWTX N/A
- Support Level
- AMBO $2.45
- DWTX N/A
- Resistance Level
- AMBO $3.14
- DWTX N/A
- Average True Range (ATR)
- AMBO 0.30
- DWTX 0.00
- MACD
- AMBO -0.02
- DWTX 0.00
- Stochastic Oscillator
- AMBO 19.86
- DWTX 0.00
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is a provider of educational and career enhancement services in China. It operates through CP&CE Programs. The CP&CE Programs include tutoring services and career enhancement services. Geographically all the operations function in the United States and Foreign countries.
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.